Back to Faculty
Co-Chair

Kathleen Moore

MD, MS
Deputy Director and Director of Phase 1
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center

Kathleen Moore is a Professor in the Section of Gynecologic Oncology, Deputy Director and Director of the Phase I Program for the Buffett Cancer Center at the University of Nebraska Medical Center. She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master's degree in epidemiology. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. She has published over 400 peer-reviewed publications and has a clinical research interest in drug development and phase I-3 clinical trials.

2026 Sessions

Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

  • Moderator
    • Kathleen Moore
  • Presenter
    • Angeles Secord
    • Debra Richardson
Gynecological Cancers

Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

  • Moderator
    • Kathleen Moore
  • Presenter
    • John Diaz
    • John Diaz
    • Brian Slomovitz
Gynecological Cancers

Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations,

  • Moderator
    • Kathleen Moore
  • Presenter
    • Linda Duska
    • Rebecca Porter
Gynecological Cancers

Recurrent Ovarian Cancer in the ADC Era: Mirvetuximab and Emerging ADCs Should Define Treatment Selection by Biomarker vs Platinum Sensitivity Still Rules: Sequencing, Not Target Expression, Should Drive Decisions

  • Moderator
    • Kathleen Moore
  • Presenter
    • Marina Frimer
    • Rebecca Porter
Gynecological Cancers

First-Line Advanced/Recurrent Endometrial Cancer: Chemo-Immunotherapy Is the New Standard for All Comers vs pMMR/MSS Disease Demands a Different Strategy: Targeted Combinations and Molecular Subtyping Over Reflexive IO

  • Moderator
    • Kathleen Moore
  • Presenter
    • Bhavana Pothuri
    • Oladapo Yeku
Gynecological Cancers
Back to top